Cytogen

Cytogen Equity

The The Equity of Cytogen (217330.KQ) as of Nov 19, 2026 is 35.56 B KRW. In the previous year, The Equity was 48.58 B KRW — a change of -26.80% (lower).

Equity

35.56 BKRW

YoY

-26.80%

Last updated:

In 2025, Cytogen's equity was 35.56 B KRW, a -26.80% increase from the 48.58 B KRW equity in the previous year.

The Cytogen Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
22.04 B KRW
Jan 1, 2019
17.92 B KRW
Jan 1, 2020
18.34 B KRW
Jan 1, 2021
23.01 B KRW
Jan 1, 2022
5.66 B KRW
Jan 1, 2023
53.36 B KRW
Jan 1, 2024
48.58 B KRW
Jan 1, 2025
35.56 B KRW
The Cytogen Equity history
YEAREquityYoY
35.56 BKRW-26.80%
48.58 BKRW-8.94%
53.36 BKRW+843.31%
5.66 BKRW-75.42%
23.01 BKRW+25.48%
18.34 BKRW+2.33%
17.92 BKRW-18.70%
22.04 BKRW+365.76%
4.73 BKRW+895.21%
475.51 MKRW-82.13%
2.66 BKRW-99.60%
671.50 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytogen Stock analysis

What does Cytogen do? CytoGen, Inc. generates revenue through liquid biopsy application services, including biomarker discovery and verification services, which encompass CTC-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis. The company also offers liquid biopsy-based precision medical services such as companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction. Additionally, CytoGen develops and sells platforms and kits for liquid biopsy, distributing these products domestically and internationally. The company's primary customers are healthcare providers and research institutions seeking advanced cancer treatment solutions. CytoGen's biomarker discovery and verification services are utilized by medical professionals for identifying and validating cancer biomarkers, while its precision medical services support oncologists in selecting optimal therapies and monitoring treatment outcomes. The liquid biopsy platforms and kits are sold to hospitals, clinics, and laboratories that require diagnostic tools for cancer detection and management. These offerings cater to the growing demand for personalized cancer care in both domestic and global markets. The company's commercialization of companion diagnostics (CDx) development is a key revenue driver, as these diagnostics are integrated into treatment protocols to enhance therapeutic efficacy. By providing comprehensive solutions from biomarker discovery to treatment monitoring, CytoGen addresses critical needs in oncology, attracting partnerships with healthcare systems and research organizations. Its product portfolio directly supports the shift toward precision medicine in cancer care. Cytogen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cytogen's Equity

Cytogen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cytogen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cytogen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cytogen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cytogen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cytogen stock

The Equity of Cytogen is 35.56 B KRW in 2025.

The Equity of Cytogen changed from 48.58 B KRW to 35.56 B KRW, representing a -26.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cytogen since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cytogen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cytogen

All Key Metrics — Cytogen